论文部分内容阅读
目的探讨乳腺化生性癌(MBC)的临床病理特征、免疫组化及鉴别诊断,为临床诊断及治疗提供依据。方法回顾性分析2003—2014年间广东省妇幼保健院经手术和病理检查确诊的MBC 8例,讨论其组织起源、病理特点、鉴别诊断及治疗与预后。结果 8例患者年龄33~58岁(平均44岁),肿瘤直径1~5 cm。3例伴软骨肉瘤样化生,3例为鳞状细胞癌,1例同时伴有软骨肉瘤和鳞状细胞癌化生,1例为肌上皮癌亚型。8例中2例伴有腋窝淋巴结转移。结论 MBC罕见,不易明确诊断,预后较差,ER、PR和HER-2多呈(-)。目前治疗主要是手术和放疗。因此,进一步理解MBC的病理学和生物学特点对于该病的诊断及治疗具有重要意义。
Objective To investigate the clinicopathological features, immunohistochemistry and differential diagnosis of mastocarcinoma of the breast (MBC) and provide the basis for clinical diagnosis and treatment. Methods A retrospective analysis of 8 cases of MBC diagnosed by operation and pathology in Guangdong Provincial Maternal and Child Health Hospital from 2003 to 2014 was conducted to discuss the origin, pathological features, differential diagnosis, treatment and prognosis of MBC. Results Eight patients were 33- to 58-year-old (average 44 years old) with tumor diameter of 1-5cm. 3 with chondrosarcoma, 3 with squamous cell carcinoma, 1 with chondrosarcoma and squamous cell carcinomas, and 1 with myoepithelial carcinoma. In 8 cases, 2 cases were accompanied with axillary lymph node metastasis. Conclusions MBC is rare, not easy to confirm the diagnosis, the prognosis is poor, ER, PR and HER-2 mostly (-). The current treatment is mainly surgery and radiotherapy. Therefore, to further understand the pathological and biological characteristics of MBC is of great significance for the diagnosis and treatment of the disease.